GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (TSE:4974) » Definitions » EV-to-EBITDA

Takara Bio (TSE:4974) EV-to-EBITDA : 14.94 (As of May. 22, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Takara Bio EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Takara Bio's enterprise value is 円97,046 Mil. Takara Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was 円6,496 Mil. Therefore, Takara Bio's EV-to-EBITDA for today is 14.94.

The historical rank and industry rank for Takara Bio's EV-to-EBITDA or its related term are showing as below:

TSE:4974' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.32   Med: 28.23   Max: 92.97
Current: 14.94

During the past 13 years, the highest EV-to-EBITDA of Takara Bio was 92.97. The lowest was 5.32. And the median was 28.23.

TSE:4974's EV-to-EBITDA is ranked worse than
58.57% of 449 companies
in the Biotechnology industry
Industry Median: 9.97 vs TSE:4974: 14.94

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Takara Bio's stock price is 円1092.00. Takara Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円13.037. Therefore, Takara Bio's PE Ratio for today is 83.76.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Takara Bio EV-to-EBITDA Historical Data

The historical data trend for Takara Bio's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takara Bio EV-to-EBITDA Chart

Takara Bio Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.82 27.83 19.16 7.81 6.08

Takara Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.47 6.08 7.24 8.05 17.81

Competitive Comparison of Takara Bio's EV-to-EBITDA

For the Biotechnology subindustry, Takara Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takara Bio's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Takara Bio's EV-to-EBITDA falls into.



Takara Bio EV-to-EBITDA Calculation

Takara Bio's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=97045.835/6496
=14.94

Takara Bio's current Enterprise Value is 円97,046 Mil.
Takara Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円6,496 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takara Bio  (TSE:4974) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Takara Bio's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1092.00/13.037
=83.76

Takara Bio's share price for today is 円1092.00.
Takara Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円13.037.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Takara Bio EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Takara Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Takara Bio (TSE:4974) Business Description

Traded in Other Exchanges
Address
Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.

Takara Bio (TSE:4974) Headlines

No Headlines